The China Respiratory devices market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 12.5% during the forecast period.
Chronic obstructive pulmonary disease (COPD) is becoming a leading cause of morbidity and mortality in China, with tobacco smoking, biomass fuel use, and genetic susceptibility being the major risk factors. COPD poses a high economic burden with the total expenditure per patient costing 40% and nearly one-third of an average family income in urban and rural areas of China, respectively. Despite being a common, preventable, and treatable disease, COPD is the fifth leading cause of death in China. The prevalence of COPD varies among geographic regions of China between 5 and 13%, with a reported prevalence of 8.2% among people aged ≥40 years.
The major factors driving the growth of respiratory device market in China are high prevalence of respiratory diseases in China, the continuation of the economic and demographic trend, technological advancements, and increasing application of in-home care settings. The chronic respiratory diseases are the second most leading cause of death in China. Almost 50% of men in China smoke whereas the rates are significantly low among women. Chronic obstructive pulmonary disease (COPD) is found to be widespread in China with almost 100 million people suffering from chronic lung disease. The biggest preventable risk factors for the disease are cigarette smoking and air pollution and thus there are public-health priorities in China to reduce COPD-related diseases and deaths. Hence all these factors are expected to drive the overall market in China.